ReviewCanadian journal of gastroenterology = Journal canadien de gastroenterologie2012
The impact of farnesoid X receptor activation on intestinal permeability in inflammatory bowel disease.
Review in Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 72 citations in OpenAlex.
- Bile salt hydrolase activity as a rational target for MASLD therapy.Gut microbes · 2026Article
- Importance of the inflammasome in gut-brain axis: from pathological driver to therapeutic target.Inflammopharmacology · 2026Review
- Duodenal mucosal RNA-Seq identifies coordinated bile acid-axis transcriptional alterations in food-responsive enteropathy in dogs.Frontiers in veterinary science · 2026Article
- Gut-Brain Axis and Bile Acid Signaling: Linking Microbial Metabolism to Brain Function and Metabolic Regulation.International journal of molecular sciences · 2025Review
- Bidirectional Interplay Between IBD Therapies and the Gut Microbiota: A Pharmacomicrobiomic Approach to Personalized Treatment.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Advances of exosome regulating‑FXR to repair inflammatory bowel disease (Review).International journal of molecular medicine · 2025Review
- Polymorphic Variants of Selected Genes Regulating Bile Acid Homeostasis in Women with Intrahepatic Cholestasis of Pregnancy.International journal of molecular sciences · 2025Article
- Dietary bile acid supplementation improves the intestinal health and growth performance of piglets partially through the FXR/AQPs pathway.Porcine health management · 2025Article
- Collaborative Metabolism: Gut Microbes Play a Key Role in Canine and Feline Bile Acid Metabolism.Veterinary sciences · 2024Review
- Farnesoid X receptor mediates macrophage-intrinsic responses to suppress colitis-induced colon cancer progression.JCI insight · 2024Article
- Alleviation of cholestatic liver injury and intestinal permeability by lubiprostone treatment in bile duct ligated rats: role of intestinal FXR and tight junction proteins claudin-1, claudin-2, and occludin.Naunyn-Schmiedeberg's archives of pharmacology · 2023Article
- Intestinal Farnesoid X Receptor Modulates Duodenal Surface Area but Does Not Control Glucose Absorption in Mice.International journal of molecular sciences · 2023Article
- Bile acids supplementation modulates lipid metabolism, intestinal function, and cecal microbiota in geese.Frontiers in microbiology · 2023Article
- FXR mediates ILC-intrinsic responses to intestinal inflammation.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Effects of Intestinal FXR-Related Molecules on Intestinal Mucosal Barriers in Biliary Tract Obstruction.Frontiers in pharmacology · 2022Article
- Ginsenoside Rc attenuates DSS-induced ulcerative colitis, intestinal inflammatory, and barrier function by activating the farnesoid X receptor.Frontiers in pharmacology · 2022Article
- The immune response as a therapeutic target in non-alcoholic fatty liver disease.Frontiers in immunology · 2022Review
- Farnesoid-X receptor as a therapeutic target for inflammatory bowel disease and colorectal cancer.Frontiers in pharmacology · 2022Review
- Bile acids in immunity: Bidirectional mediators between the host and the microbiota.Frontiers in immunology · 2022Review
- Bile Acids and the Microbiome: Making Sense of This Dynamic Relationship in Their Role and Management in Crohn's Disease.Canadian journal of gastroenterology & hepatology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The most important function of the intestinal mucosa is to form a barrier that separates luminal contents from the intestine. Defects in the intestinal epithelial barrier have been observed in several intestinal disorders such as inflammatory bowel disease (IBD). Recent studies have identified a number of factors that contribute to development of IBD including environmental triggers, genetic factors, immunoregulatory defects and microbial exposure. The current review focuses on the influence of the farnesoid X receptor (FXR) on the inhibition of intestinal inflammation in patients with IBD. The development and investigation of FXR agonists provide strong support for the regulatory role of FXR in mucosal innate immunity. Activation of FXR in the intestinal tract decreases the production of proinflammatory cytokines such as interleukin (IL) 1-beta, IL-2, IL-6, tumour necrosis factor-alpha and interferon-gamma, thus contributing to a reduction in inflammation and epithelial permeability. In addition, intestinal FXR activation induces the transcription of multiple genes involved in enteroprotection and the prevention of bacterial translocation in the intestinal tract. These data suggest that FXR agonists are potential candidates for exploration as a novel therapeutic strategy for IBD in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.